Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XXB750 in heart failure with reduced or mildly reduced ejection fraction
NCT05328752Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of xxb750 in heart failure with reduced ejection fraction (HFrEF) and heart failure with mildly reduced ejection fraction (HFmrEF) (4 cohorts), sponsored by Novartis. Primary endpoint: Adverse Events at 146 days. Started May 2022; status: completed.
02
Drugs
xxb750
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with mildly reduced ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NCT05328752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328752.